Single-dose Study of [14C]PF-05221304 Metabolism and Excretion in Healthy Adult Male Subjects
| Status: | Completed |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 18 - 45 |
| Updated: | 12/6/2018 |
| Start Date: | April 18, 2018 |
| End Date: | June 13, 2018 |
A Phase 1, Open Label, Single-period, Non-randomized Study To Evaluate The Pharmacokinetics, Excretion, Mass Balance, And Metabolism Of [14c]Pf-05221304 Administered Orally To Healthy Adult Male Subjects
The purpose of the study is to characterize the absorption, distribution, metabolism, and
excretion (ADME) of a single oral dose of [14C]PF-05221304 in Healthy Adult Male Subjects
excretion (ADME) of a single oral dose of [14C]PF-05221304 in Healthy Adult Male Subjects
Inclusion Criteria:
1. Ages of 18 and 45 years, inclusive.
2. Body mass index (BMI) of >= 17.5 and <= 30.4 kg/m2
3. Total body weight > 50 kg (110 lb).
Exclusion Criteria:
1. Evidence or history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, allergic
disease or clinical findings.
We found this trial at
1
site
Click here to add this to my saved trials
